Andy Darlington: Randomized Evidence for Catheter-Based Treatment of Intermediate-High-Risk PE
Andy Darlington, Global Partnerships Manager of Medical Devices at Radcliffe Group, shared a post on LinkedIn:
“In this clip, Prof Lukas Hobohm reviews the findings from the HI-PEITHO randomised controlled trial.
The trial compared EKOS plus anticoagulation with anticoagulation alone in 544 patients with intermediate-high-risk PE, assessing whether intervention could reduce early PE-related complications.
The discussion explores the reduction in the composite outcome of PE-related mortality, cardiopulmonary decompensation or PE recurrence within seven days, alongside findings on major bleeding and hospital length of stay.
Watch the clip below for insights into how randomised evidence is shaping treatment strategies for intermediate-high-risk PE.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C
-
Nov 16, 2026, 12:52Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments
-
Nov 16, 2026, 12:44Stefan Prendić: How Intronic Variants Affect Rh Blood Group Antigen Expression
-
Nov 16, 2026, 12:26Samwel Mikaye: Understanding Warfarin and Its Clinical Management
-
Nov 16, 2026, 12:14Sophia Delicou: Ensuring Lifelong Health Beyond Stem Cell Transplantation
-
Nov 16, 2026, 12:06Edward Lee Carter: Has PEPPER Changed the Role of Aspirin in Arthroplasty VTE Prophylaxis?
-
Nov 16, 2026, 11:53Eduardo Ortiz Bello: The Endothelium in Hemostasis and Microcirculation
-
Nov 16, 2026, 11:51Phil Spinella: Advancing Transfusion Medicine Through Collaboration